By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – South Korean life sciences company Chemizon, a division of Optomagic, said today that it will support Shenogen Pharma Group's drug development programs aimed at developing small molecule therapeutics for cancer and endocrine disorders.

Chemizon will be responsible for a range of services and activities, including lead optimization, assay development, computational chemistry, animal pharmacology, and absorption, distribution, metabolism, and excretion processes.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.